Alphabet’s Isomorphic Labs draws VC interest as it seeks to turn AI protein modeling into drug discovery engine

Isomorphic Labs, an Alphabet spin‑off, is building a platform that uses its protein‑modeling AI to create new medicines.

The secretive startup has not been actively raising money, but venture firm Thrive Capital recently flew to London to pitch a potential stake.

Investors view the effort as high‑risk because the company is tied to Google, yet they are attracted by the challenge of applying cutting‑edge AI to drug discovery.

Success will hinge on whether the modeling tool can become a reliable engine for generating drug candidates, a goal that remains distant for now.